Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 17/20 | 0.53 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16441213 | 0.89 | GPR119 (0.44) | GPR119 | |
| SCHEMBL525591 | 0.89 | GPR119 (0.59) | GPR119HPGDKDM4EMEN1ALDH1A1 | |
| SCHEMBL426116 | 0.87 | PRMT5 (0.54) | GPR119HPGDKDM4EMEN1USP2 | |
| SCHEMBL17828657 | 0.87 | GPR119 (0.53) | GPR119 | |
| SCHEMBL426151 | 0.87 | GPR119 (0.53) | GPR119 | |
| SCHEMBL14937964 | 0.86 | GPR119 (0.64) | GPR119MEN1KMT2A | |
| SCHEMBL16432942 | 0.86 | GPR119 (0.50) | GPR119 | |
| SCHEMBL425150 | 0.85 | FAAH (0.47) | GPR119HPGDKDM4EMEN1USP2 | |
| SCHEMBL14937903 | 0.85 | GPR119 (0.58) | GPR119 | |
| SCHEMBL17853477 | 0.84 | GPR119 (0.51) | GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160166560-A1 | Urea Compounds and Their Use as FAAH Enzyme Inhibitors | BIAL-PORTELA & CA, S.A. (PT) | 2016-06-16 | — | — | US | disclosed |
| WO-2015016728-A1 | UREA COMPOUNDS AND THEIR USE AS FAAH ENZYME INHIBITORS | BIAL - PORTELA & Cª, S.A. (PT) | 2015-02-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160166560-A1 | Urea Compounds and Their Use as FAAH Enzyme Inhibitors | FAAH, FAAH2, HRH2 | GPR119 436/4885HPGD 491/4885KDM4E 998/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.